NICE draft guidance refuses pembrolizumab plus axitinib combination
The National Institute for Health and Care Excellence (NICE) have issued [...]
Lenvatinib plus pembrolizumab shows promise in solid tumours
The combination of lenvatinib plus pembrolizumab has shown promise in [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Pilot study of radiation therapy plus pembrolizumab for kidney cancer
A recent publication in the American Journal of Clinical Oncology [...]
Deciding on the ideal first-line treatment for rare and advanced kidney cancer
Currently, doctors are unsure which is the best first-line treatment [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer
Interim results from an ongoing clinical trial of lenvatinib and [...]
Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer
A recent phase 1b clinical trial investigated the use of [...]
European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase 3 KEYNOTE-426 [...]
European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
